THCA will play a pivotal role in  cannabis medicine as the industry propels forward. Here are some of the  potential benefits studies have started to unveil:

• Anti-inflammatory properties for treatment of arthritis and lupus
• Neuroprotective properties for treatment of neurodegenerative diseases
• Anti-emetic properties for treatment of nausea and appetite loss
• Anti-proliferative properties noted in studies of prostate cancer

Other possible medicinal avenues supported by patient stories include insomnia, muscle spasms, and pain.  Now you can fully understand what THCA means for  the future of cannabinoid-based medicines. 

CBGA has been found to act on very specific physiological systems and problems, and results for medicinal use are promising:

• Endocannabinoid receptors are prevalent in eye structures, and  interestingly, CBGA is thought to be particularly effective in treating  glaucoma because it reduces intraocular pressure. It is a powerful vasodilator and has neuroprotective effects to boot.
• CBGA was found to be effective in decreasing the inflammation characteristic of inflammatory bowel disease.
• In a recent 2015 study, CBGA was shown to protect neurons in Huntington’s disease, which is characterized by nerve cell degeneration in the brain.
• CBGA is showing great promise as a cancer fighter. Specifically, CBGA  was shown to block receptors that cause cancer cell growth. In one such  study, it was shown to inhibit the growth of colorectal cancer cells, thereby slowing colon cancer growth. CBGA inhibited tumors and  chemically-induced colon carcinogenesis, therefore demonstrating a very  exciting possibility for a cure for colorectal cancer.
• European research shows evidence that CBGA is an effective antibacterial agent, particularly against methicillin-resistant Staphylococcus aureus (MRSA) microbial strains resistant to several classes of drugs. Since  the 1950s, topical formulations of cannabis have been effective in skin  infections, but researchers at the time were unaware of the plant’s  chemical composition.
• In a very recent 2017 study, researchers showed that a form of CBGA  purified to remove delta-9 THC was a very effective appetite stimulant. This may lead to a novel non-psychotropic therapeutic option  for cachexia, the muscle wasting and severe weight loss seen in late stage cancer and other diseases.
• In a study that looked at the effects of five different cannabinoids on bladder contractions, CBGA tested best at inhibiting muscle contractions, so it may be a future tool in preventing bladder dysfunction disorders.

Scientists are excited about these initial CBGA results and are  promoting future research with CBGA alone or CBGA in combination with  other cannabinoids and therapies for the treatment of multiple maladies.  Because it is non-psychotropic, CBGA has a promising wide range of  potential applications not only for the problems mentioned above, but  also as an analgesic, therapy for psoriasis, and as an antidepressant.